{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:47Z","timestamp":1760775047270,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"am","delay-in-days":727,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bmcl.2023.129151","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T12:38:22Z","timestamp":1674218302000},"page":"129151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design and synthesis of novel orexin 2 receptor agonists with a 1,3,5\u2011trioxazatriquinane skeleton"],"prefix":"10.1016","volume":"82","author":[{"given":"Mao","family":"Amezawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriki","family":"Kutsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129151_b0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2023.129151_b0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrn3837","article-title":"The role of orexin in motivated behaviours","volume":"15","author":"Sakurai","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmcl.2023.129151_b0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0166-2236(00)01594-0","article-title":"The hypocretin\/orexin ligand\u2013receptor system: implications for sleep and sleep disorders","volume":"23","author":"Kilduff","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bmcl.2023.129151_b0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmcl.2023.129151_b0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature06310","article-title":"Neural substrates of awakening probed with optogenetic control of hypocretin neurons","volume":"450","author":"Adamantidis","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129151_b0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.yfrne.2007.08.001","article-title":"Orexin neuronal circuitry: role in the regulation of sleep and wakefulness","volume":"29","author":"Ohno","year":"2008","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.bmcl.2023.129151_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0092-8674(02)09256-5","article-title":"Addendum: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2023.129151_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0167-0115(99)00076-2","article-title":"Orexins and orexin receptors: implication in feeding behavior","volume":"85","author":"Sakurai","year":"1999","journal-title":"Regul Pept"},{"key":"10.1016\/j.bmcl.2023.129151_b0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129151_b0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2008.06.060","article-title":"Role of lateral hypothalamic orexin neurons in reward processing and addiction","volume":"56","author":"Aston-Jones","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2023.129151_b0055","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1460-9568.2009.06952.x","article-title":"Hypocretin\/orexin contributes to the expression of some but not all forms of stress and arousal","volume":"30","author":"Furlong","year":"2009","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bmcl.2023.129151_b0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2023.129151_b0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-444-59489-1.00009-4","article-title":"Orexin, stress, and anxiety\/panic states","volume":"198","author":"Johnson","year":"2012","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bmcl.2023.129151_b0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2023.129151_b0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.bmcl.2023.129151_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2023.129151_b0085","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2023.129151_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.bmcl.2023.129151_b0095","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/ana.10164","article-title":"Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy","volume":"51","author":"Schuld","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bmcl.2023.129151_b0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/sleep\/26.5.555","article-title":"Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children","volume":"26","author":"Kubota","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.bmcl.2023.129151_b0105","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129151_b0110","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2023.129151_b0115","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1021\/acs.jmedchem.1c00841","article-title":"Discovery of arylsulfonamides as dual orexin receptor agonists","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129151_b0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41467-021-21087-6","article-title":"Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation","volume":"12","author":"Hong","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2023.129151_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128530","article-title":"Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton","volume":"59","author":"Hino","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129151_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128555","article-title":"Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: switching of receptor selectivity by chirality on the tetralin ring","volume":"60","author":"Iio","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129151_b0135","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1021\/acsmedchemlett.2c00358","article-title":"Orexin receptor agonists as possible treatment for narcolepsy and idiopathic hypersomnia","volume":"13","author":"Abdel-Magid","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129151_b0140","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/acsmedchemlett.2c00268","article-title":"Novel macrocyclic urea orexin receptor agonists for treating sleep disorders","volume":"13","author":"Sabnis","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129151_b0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129151_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173464","article-title":"Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model","volume":"220","author":"Ishikawa","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bmcl.2023.129151_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172794","article-title":"TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice","volume":"187","author":"Yukitake","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bmcl.2023.129151_b0160","unstructured":"Yanagisawa M. Small-molecule agonists for type-2 orexin receptor. US Patent. US20100150840A1, 2010."},{"key":"10.1016\/j.bmcl.2023.129151_b0165","article-title":"Design and synthesis of orexin 1 receptor-selective agonists","author":"Iio","year":"2022","journal-title":"ChemRxiv."},{"key":"10.1016\/j.bmcl.2023.129151_b0170","unstructured":"Bogen SL, Clausen DJ, Guiadeen DG, et al. 5-alkyl pyrrolidine orexin receptor agonists. US Patent. US11098029B2, 2021."},{"key":"10.1016\/j.bmcl.2023.129151_b0175","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejmech.2018.07.040","article-title":"Azulene-based compounds for targeting orexin receptors","volume":"157","author":"Leino","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129151_b0180","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cmdc.201900074","article-title":"Structure-activity relationships of 1-benzoylazulenes at the OX1 and OX2 orexin receptors","volume":"14","author":"Turku","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2023.129151_b0185","unstructured":"Armacost KA, Chiriac MI, Hurzy DM, et al. Macrocyclic urea orexin receptor agonists. World Patent. WO2022094012A1, 2022."},{"key":"10.1016\/j.bmcl.2023.129151_b0190","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ardp.201500031","article-title":"Synthesis of novel triplets with a 1,3,5-trioxazatriquinane skeleton and their pharmacologies for opioid receptors","volume":"348","author":"Nagase","year":"2015","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmcl.2023.129151_b0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3987\/COM-18-S(T)40","article-title":"Synthesis of Novel 1,3-Dioxa-5-thiazatriquinane and 1-Oxa-3,5-dithiazatriquinane derivatives and their pharmacologies","volume":"97","author":"Ohshita","year":"2018","journal-title":"Heterocycles"},{"key":"10.1016\/j.bmcl.2023.129151_b0200","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1021\/ml5000542","article-title":"Synthesis and pharmacology of a novel \u03ba opioid receptor (KOR) agonist with a 1,3,5-trioxazatriquinane skeleton","volume":"5","author":"Hirayama","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129151_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114505","article-title":"Discovery of novel orexin receptor antagonists using a 1,3,5-trioxazatriquinane bearing multiple effective residues (TriMER) library","volume":"240","author":"Saitoh","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129151_b0210","series-title":"A Medicinal Chemistry: Molecular and Biochemical Approach","first-page":"85","author":"Nogrady","year":"2005"},{"key":"10.1016\/j.bmcl.2023.129151_b0215","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1038\/s41467-022-30601-3","article-title":"Molecular mechanism of the wake-promoting agent TAK-925","volume":"13","author":"Yin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2023.129151_b0220","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","article-title":"Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis","volume":"63","author":"Rappas","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129151_b0225","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1021\/ja00538a077","article-title":"The first practical method for asymmetric epoxidation","volume":"102","author":"Katsuki","year":"1980","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2023.129151_b0230","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1021\/jo00109a004","article-title":"A new asymmetric synthesis of \u03b1-methylcysteines via chiral aziridines","volume":"60","author":"Shao","year":"1995","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmcl.2023.129151_b0235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/ja00783a034","article-title":"Nuclear magnetic resonance enantiomer regents. Configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, O-methylmandelate, and \u03b1-methoxy-\u03b1-trifluoromethylphenylacetate (MTPA) esters","volume":"95","author":"Dale","year":"1973","journal-title":"J Am Chem Soc"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2300029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2300029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:10Z","timestamp":1760773570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2300029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":47,"alternative-id":["S0960894X2300029X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129151","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel orexin 2 receptor agonists with a 1,3,5\u2011trioxazatriquinane skeleton","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129151"}}